Photo of Christopher L. Corless, M.D., Ph.D.

Christopher L. Corless M.D., Ph.D.

  • (855) 535-1522
    • Professor of Medicine School of Medicine
    • Vice Chair, Research
    • Chief Medical Officer, Knight Diagnostic Laboratories

Dr. Corless pursues research on immunohistochemical and molecular testing to novel therapeutic targets.

Dr. Corless' clinical interests include liver transplant pathology, gastrointestinal pathology and genitourinary pathology. He currently serves as the medical director of the Cancer Pathology Share Resource. Dr. Corless has been board certified in anatomic pathology since 1993. He received both his M.D. and Ph.D. from the Washington University School of Medicine, St. Louis, in 1988.

Read more

Education

  • M.D., Ph.D., Washington University School of Medicine, St. Louis Missouri 1988
  • Residency:

    • Anatomic Pathology, Brigham & Women's Hospital, Boston, 1988-1990
  • Fellowship:

    • Urologic Pathology, Brigham & Women's Hospital, Boston, 1992-1993
    • Gastrointestinal Pathology, Brigham & Women's Hospital, Boston, 1990-1992
  • Certifications:

    • Anatomic Pathology, American Board of Pathology, 1993

Memberships and associations

  • Am. Association for Cancer Research

Publications

  • "Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results : Analysis of Phase 3 SWOG Intergroup Trial S0033." JAMA oncology In: , Vol. 3, No. 7, 01.07.2017, p. 944-952.
  • "Breast cancer histopathology image analysis pipeline for tumor purity estimation."  2017 IEEE 14th International Symposium on Biomedical Imaging, ISBI 2017. IEEE Computer Society, 2017. p. 1137-1140 7950717.
  • "Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors." Expert Review of Molecular Diagnostics In: , Vol. 17, No. 5, 04.05.2017, p. 445-457.
  • "Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels : A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists." Journal of Molecular Diagnostics In: , Vol. 19, No. 3, 01.05.2017, p. 341-365.
  • "MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation." Nature Communications In: , Vol. 8, 14674, 08.03.2017.
  • "Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions." Journal of Thoracic Oncology  In: , 25.02.2017.
  • "Biliary adenofibroma of liver." American Journal of Surgical Pathology In: , Vol. 41, No. 4, 2017, p. 499-505.
  • "Defining the impact of adjuvant therapy in molecularly defined subsets of gastrointestinal stromal tumor : From lumping to splitting." JAMA Oncology In: , Vol. 3, No. 5, 2017, p. 597-599.
  • "FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors." Journal of Translational Medicine In: , Vol. 14, No. 1, 339, 14.12.2016.
  • "Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping." Reproductive Sciences In: , Vol. 23, No. 11, 01.11.2016, p. 1575-1579.
  • "Next-Generation Sequencing in Cancer Diagnostics." Journal of Molecular Diagnostics In: , Vol. 18, No. 6, 01.11.2016, p. 813-816.
  • "Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy." Annals of Oncology  In: , Vol. 27, No. 9, mdw228, 01.09.2016, p. 1794-1799.
  • "Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour." European Journal of Cancer  In: , Vol. 61, 01.07.2016, p. 94-101.
  • "IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma." Scientific Reports  In: , Vol. 6, 27012, 03.06.2016.
  • "A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing." Journal of Molecular Diagnostics In: , Vol. 18, No. 2, 01.03.2016, p. 165-175.
  • "Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity." Urologic Oncology: Seminars and Original Investigations  In: , Vol. 34, No. 1, 01.01.2016.
  • "S0502 : A SWOG phase III randomized study of imatinib, with or without bevacizumab, in patients with untreated metastatic or unresectable gastrointestinal stromal tumors." Oncologist  In: , Vol. 20, No. 12, 17.11.2015, p. 1353-1354.
  • "Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-Mutated gastrointestinal stromal tumors." American Journal of Clinical Pathology In: , Vol. 144, No. 5, 01.11.2015, p. 782-789.
  • "Template for reporting results of biomarker testing of specimens from patients with gastrointestinal stromal tumors." Archives of Pathology and Laboratory Medicine  In: , Vol. 139, No. 10, 01.10.2015, p. 1271-1275.
  • "SDHC methylation in gastrointestinal stromal tumors (GIST) : A case report." BMC Medical Genetics In: , Vol. 16, No. 1, 87, 28.09.2015.
  • "Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease." PLoS One In: , Vol. 10, No. 8, e0136407, 28.08.2015.
  • "SWOG S0809 : A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma." Journal of Clinical Oncology In: , Vol. 33, No. 24, 20.08.2015, p. 2617-2622.
  • "KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GI stromal tumors : Relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation." Journal of Clinical Oncology In: , Vol. 33, No. 22, 01.08.2015, p. e93-e96.
  • "The Signature Program : Bringing the Protocol to the Patient." Clinical Pharmacology and Therapeutics In: , Vol. 98, No. 2, 01.08.2015, p. 124-126.
  • "Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition." Clinical Cancer Research  In: , Vol. 21, No. 10, 15.05.2015, p. 2289-2296.
  • "Hybrid capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers." Applied Immunohistochemistry and Molecular Morphology In: , Vol. 23, No. 4, 22.04.2015, p. 266-272.
  • "Molecular profiling and targeted therapy for advanced thoracic malignancies a biomarker-derived, multiarm, multihistology phase ii basket trial." Journal of Clinical Oncology  In: , Vol. 33, No. 9, 20.03.2015, p. 1000-1007.
  • "Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance." Cancer Research In: , Vol. 75, No. 5, 01.03.2015, p. 880-891.
  • "Novel mutations in neuroendocrine carcinoma of the breast : Possible therapeutic targets." Applied Immunohistochemistry and Molecular Morphology In: , Vol. 23, No. 2, 28.02.2015, p. 97-103.
  • "Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data." Journal of Molecular Diagnostics In: , Vol. 17, No. 1, 01.01.2015, p. 53-63.

Additional information

Edit profile